A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma

Therapeutic Drug Monitoring

Volumn 32, Issue 2, 2010, Pages 200-205

  Polillo, Marialuisa ^a   Tascini, Carlo ^b   Lastella, Marianna ^a   Malacarne, Paolo ^c   Ciofi, Laura ^a   Viaggi, Bruno ^c   Bocci, Guido ^a   Menichetti, Francesco ^b   Danesi, Romano ^a   Del Tacca, Mario ^a   Di Paolo, Antonello ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Unit of Infectious Diseases   (Italy)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Daptomycin; High performance liquid chromatography; Linezolid; Therapeutic drug monitoring

Indexed keywords

DAPTOMYCIN; LINEZOLID; ACETAMIDE DERIVATIVE; OXAZOLIDINONE DERIVATIVE;

ACCURACY; ADULT; ANALYTIC METHOD; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CALIBRATION; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; GRAM POSITIVE INFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK PATIENT; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS EPIDERMIDIS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCUS EPIDERMIDIS; VALIDATION PROCESS; VANCOMYCIN RESISTANT ENTEROCOCCUS; AGED; BLOOD; COMPARATIVE STUDY; MIDDLE AGED; PHARMACEUTICS; PROCEDURES; STANDARDS;

ACETAMIDES; ADULT; AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DAPTOMYCIN; FEMALE; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; TECHNOLOGY, PHARMACEUTICAL;

EID: 77950225669     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181d3f5cb     Document Type: Article

References (31)

1. Menichetti F. Current and emerging serious Gram-positive infections. Clin Microbiol Infect. 2005;11(Suppl 3):22-28.
2. Rossolini GM, Mantengoli E. Antimicrobial resistance in Europe and its potential impact on empirical therapy. Clin Microbiol Infect. 2008; 14(Suppl 6):2-8.
3. Jenkins SG. Antimicrobial susceptibility patterns in the United States and globally: findings of the TRUST and GLOBAL surveillance studies. Postgrad Med. 2008;120:5-7.
4. Metzger R, Bonatti H, Sawyer R. Future trends in the treatment of serious Gram-positive infections. Drugs Today (Barc). 2009;45:33-45.
5. Manfredi R. Update on the appropriate use of linezolid in clinical practice. Ther Clin Risk Manag. 2006;2:455-464.
6. Tascini C, Gemignani G, Doria R, et al. Linezolid treatment for Gram-positive infections: a retrospective comparison with teicoplanin. J Chemother. 2009;21:311-316.
7. Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents. 2004;23:113-119.
8. Sauermann R, Rothenburger M, Graninger W, et al. Daptomycin: a review 4 years after first approval. Pharmacology. 2008;81:79-91.
9. Baltz RH. Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr Opin Chem Biol. 2009;13:144-151.
10. Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003;36:159-168.
11. Senneville E, Legout L, Valette M, et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther. 2006;28:1155-1163.
12. Boak LM, Li J, Rayner CR, et al. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrob Agents Chemother. 2007;51:1287-1292.
13. Livermore DM. Future directions with daptomycin. J Antimicrob Chemother. 2008;62(Suppl 3):iii41-iii49.
14. Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J. 2003;22:S153-S157.
15. Fiaccadori E, Maggiore U, Rotelli C, et al. Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation. Nephrol Dial Transplant. 2006; 21:1402-1406.
16. Lovering AM, Le Floch R, Hovsepian L, et al. Pharmacokinetic evaluation of linezolid in patients with major thermal injuries. J Antimicrob Chemother. 2009;63:553-559.
17. Bubalo JS, Munar MY, Cherala G, et al. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother. 2009;53:428-434.
18. Salama NN, Segal JH, Churchwell MD, et al. Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis. Clin J Am Soc Nephrol. 2009;4:1190-1194.
19. Wagner CC, Steiner I, Zeitlinger M. Daptomycin elimination by CVVH in vitro: evaluation of factors influencing sieving and membrane adsorption. Int J Clin Pharmacol Ther. 2009;47:178-186
20. Mohr JF 3rd, Ostrosky-Zeichner L, Wainright DJ, et al. Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury. Antimicrob Agents Chemother. 2008;52:1891-1893.
21. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48:63-68.
22. Lode HM. Clinical impact of antibiotic-resistant Gram-positive pathogens. Clin Microbiol Infect. 2009;15:212-217.
23. Adembri C, Fallani S, Cassetta MI, et al. Linezolid pharmacokinetic/ pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents. 2008;31:122-129.
24. Thallinger C, Buerger C, Plock N, et al. Effect of severity of sepsis on tissue concentrations of linezolid. J Antimicrob Chemother. 2008;61: 173-176.
25. Craig WA. Does the dose matter? Clin Infect Dis. 2001;33(Suppl 3): S233-S237.
26. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46: 2723-2726.
27. Dandekar PK, Tessier PR, Williams P, et al. Determination of the pharmacodynamic profile of daptomycin against Streptococcus pneumo-niae isolates with varying susceptibility to penicillin in a murine thigh infection model. Chemotherapy. 2004;50:11-16.
28. Yates CJ, May K, Hale T, et al. Wound chronicity, inpatient care and chronic kidney disease predispose to MRSA infection in diabetic foot ulcers. Diabetes Care. 2009;32:1907-1909.
29. Esposito S, Leone S, Noviello S, et al. Foot infections in diabetes (DFIs) in the out-patient setting: an Italian multicentre observational survey. Diabet Med. 2008;25:979-984.
30. Benvenuto M, Benziger DP, Yankelev S, et al. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50:3245-3249.
31. DeRyke CA, Sutherland C, Zhang B, et al. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species. Antimicrob Agents Chemother. 2006;50:3529-3534.